Evaluation of the Automated Immunohematology Analyzer DAYMATE M.
- Author:
Jaeeun YOO
1
;
Hain YU
;
Hyunyu CHOI
;
Gyoo Whung LEE
;
Young Sun SONG
;
Seungok LEE
;
Dong Wook JEKARL
;
Yonggoo KIM
Author Information
- Publication Type:Original Article
- Keywords: Automated immunohematology analyzer; DAYMATE M; ABO blood typing
- MeSH: Blood Grouping and Crossmatching; Erythrocytes; Hematopoietic Stem Cell Transplantation; Humans; Incheon; Mass Screening; Methods; Seoul; Tissue Donors
- From:Laboratory Medicine Online 2017;7(4):163-169
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: An automated immunohematology analyzer, DAYMATE M (DAY Medical, Switzerland), has been recently developed. The potential of this analyzer to improve test results has been evaluated. METHODS: A total of 300 blood samples from Seoul St. Mary's hospital and Incheon St. Mary's hospital were tested for ABO and RhD typing. In addition, 336 antibody screening test (AST) samples and 82 patients treated with hematopoietic stem cell transplantation (HSCT) were included. AST results by DAYMATE M were compared with those obtained by a manual method using DS-Screening II (Bio-Rad Laboratories, Switzerland) and red blood cells from Selectogen (Ortho-Clinical diagnostics Inc., USA). RESULTS: Of the 300 patients enrolled, 87, 73, 79, and 61 had type A, B, O, and AB blood, respectively. The concordance rate was 99.9% for cell typing and 97.0% for serum typing. One discordant case was classified as type B instead of AB, and six discordant serum-typing cases were type A, but classified as type AB. Among the 336 AST samples, the concordance rate was 93.2%. From 136 positive cases, six were discordant. Within the 82 HSCT-treated patients, the concordance rate for ABO blood typing was 92.2%. Among the six discordant cases, DAYMATE M typed four cases as donor type where the standard method typed them as the recipient blood type. CONCLUSIONS: The DAYMATE M automated immunohematology analyzer performs reliably for ABO and RhD typing, as well as for ASTs and on samples from patients treated with HSCT.
